Astellas Pharma, Inc.
http://www.astellas.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Astellas Pharma, Inc.
Annexon’s ANX007 Misses GA Endpoint, But May Have Visual Acuity Path Forward
The ARCHER study did not show improvement in lesion growth, but still showed an improvement in best corrected visual acuity, potentially opening a pathway toward a pivotal trial.
Everything’s Coming Up Pfizer: The Biggest Of Pharma Firms Leads Industry In Pending Applications For US FDA Approval
Pfizer’s lineup of novel agents under review stands at seven, while no other big pharma has more than two novel candidates; Sanofi is tops in recent approvals since 2021, with seven novel agents cleared, but has no pending NMEs.
Industry Leaders Speculate On FTC Vs. Amgen/Horizon Fallout
Pfizer chief clinical officer William Pao, Roche pharma CEO Teresa Graham and others weighed in on what FTC’s action could mean for pharma M&A at the Financial Times Pharma Summit.
TytoCare Plans To Integrate More AI Into Diagnostics To Drive Longitudinal ‘Family’ Care At Home
Medtech Insight recently sat down with TytoCare’s chief commercial officer Tamir Gotfried to discuss plans for driving virtual care in the home, and engage physicians and consumers, at a time when pandemic-era state-level telehealth flexibilities continue to evolve.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Advanced Cell Technology, Inc.
- Agensys, Inc.
- Audentes Therapeutics, Inc.
- Fujisawa GmbH
- Ganymed Pharmaceuticals AG GmbH
- iota Biosciences
- Mytogen, Inc.
- Nanna Therapeutics Limited
- Perseid Therapeutics LLC
- Potenza Therapeutics Inc.
- Ocata Therapeutics, Inc.
- OSI Pharmaceuticals, LLC (Cell Pathways
- Prosidion)
- Yamanouchi Pharmaceutical Co., Ltd.
- Ogeda S.A.
- Mitobridge, Inc.
- Mitokyne, Inc.
- Quethera Limited
- Universal Cells, Inc.
- Xyphos Biosciences, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice